Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges

M Kokkorakis, C Boutari, MA Hill… - Metabolism …, 2024 - metabolismjournal.com
Over the past decade, there have been several guideline updates for the diagnosis and
management of non-alcoholic fatty liver disease (NAFLD), which is the most common …

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways

OO Badmus, SA Hillhouse, CD Anderson… - Clinical …, 2022 - portlandpress.com
The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in
the liver in combination with metabolic dysfunction in the form of overweight or obesity and …

From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic …

M Kokkorakis, C Boutari, N Katsiki… - Metabolism-Clinical …, 2023 - metabolismjournal.com
Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic condition closely
associated with genetic predisposition and/or obesity, lipodystrophy, and insulin resistance …

[HTML][HTML] Theabrownin and Poria cocos Polysaccharide Improve Lipid Metabolism via Modulation of Bile Acid and Fatty Acid Metabolism

J Wang, D Zheng, F Huang, A Zhao, J Kuang… - Frontiers in …, 2022 - frontiersin.org
Nonalcoholic fatty liver disease (NAFLD) is prevalent worldwide, while no pharmaceutical
treatment has been approved. Natural herbs are promising for their amelioration effect on …

Green Pea (Pisum sativum L.) Hull Polyphenol Extract Alleviates NAFLD through VB6/TLR4/NF-κB and PPAR Pathways

F Guo, H Xiong, R Tsao, F Shahidi, X Wen… - Journal of Agricultural …, 2023 - ACS Publications
Green pea hull is a processing byproduct of green pea and rich in polyphenols.
Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic disease characterized by …

Liver fat as risk factor of hepatic and cardiometabolic diseases

M Demir, SR Bornstein, CS Mantzoros… - Obesity …, 2023 - Wiley Online Library
Non‐alcoholic fatty liver disease (NAFLD) is a disorder characterized by excessive
accumulation of fat in the liver that can progress to liver inflammation (non‐alcoholic …

[HTML][HTML] Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease

GE Chung, SJ Yu, JJ Yoo, Y Cho, K Lee, DW Shin… - BMC medicine, 2023 - Springer
Background Metabolic-associated fatty liver disease (MAFLD) encompasses diverse
disease groups with potentially heterogeneous clinical outcomes. We investigated the risk of …

[HTML][HTML] Targeting gut microbiota with natural polysaccharides: effective interventions against high-fat diet-induced metabolic diseases

CY Sun, ZL Zheng, CW Chen, BW Lu… - Frontiers in Microbiology, 2022 - frontiersin.org
Unhealthy diet, in particular high-fat diet (HFD) intake, can cause the development of several
metabolic disorders, including obesity, hyperlipidemia, type 2 diabetes mellitus (T2DM), non …

[HTML][HTML] The role of FGF21 and its analogs on liver associated diseases

K Falamarzi, M Malekpour, MF Tafti, N Azarpira… - Frontiers in …, 2022 - frontiersin.org
Fibroblast growth factor 21 (FGF21), a member of fibroblast growth factor family, is a
hormone-like growth factor that is synthesized mainly in the liver and adipose tissue. FGF21 …

Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids …

H Li, XK Wang, M Tang, L Lei, JR Li, H Sun, J Jiang… - Gut …, 2024 - Taylor & Francis
Gut microbiota plays an essential role in the progression of nonalcoholic fatty liver disease
(NAFLD), making the gut-liver axis a potential therapeutic strategy. Bacteroides genus, the …